Holen Sie sich die Stockscreener-App
6.46
54.49%
2.12
Schlusskurs vom Vortag:
$4.34
Offen:
$5.31
24-Stunden-Volumen:
28.27M
Relative Volume:
20.34
Marktkapitalisierung:
$537.45M
Einnahmen:
$14.20M
Nettoeinkommen (Verlust:
$-49.59M
KGV:
-7.6686
EPS:
-0.8424
Netto-Cashflow:
$-35.25M
1W Leistung:
+50.67%
1M Leistung:
+83.20%
6M Leistung:
+40.57%
1J Leistung:
+393.01%
1-Tages-Spanne:
$5.31
$7.07
1-Wochen-Bereich:
$4.28
$7.07
52-Wochen-Spanne:
$1.32
$7.07
Opus Genetics Inc Stock (IRD) Company Profile
Firmenname
Opus Genetics Inc
Sektor
Branche
Telefon
248-681-9815
Adresse
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
6.46 | 361.07M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-16 | Eingeleitet | Oppenheimer | Outperform |
| 2026-01-20 | Eingeleitet | BTIG Research | Buy |
| 2025-12-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-29 | Eingeleitet | Wedbush | Outperform |
| 2025-10-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-13 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
IRD Stock Jumps As Traders Target Gene Therapy Catalyst - timothysykes.com
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
IRD Maintained by Chardan Capital -- Price Target at $13.00 - GuruFocus
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data - TipRanks
IRD Looks 1451.8% Overvalued on GF Value™ - GuruFocus
Opus Genetics Reports Positive Interim Phase 1/2 Results for OPGx-BEST1 in BEST1-Related Retinal Diseases - Quiver Quantitative
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 - Yahoo Finance
Opus Genetics Director Cam Gallagher Exercises Warrant for 784,314 Shares, Enters 180-Day Lock-Up - Kalkine Media
Opus Genetics (IRD) director adds shares, accepts 180-day lock-up - Stock Titan
Opus Genetics (IRD) CFO stock sale mixes tax withholding and 10b5-1 plan - Stock Titan
Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026. - Pluang
Opus Genetics stock rating reaffirmed at Buy by H.C. Wainwright - Investing.com
Missed Opus Genetics' 130% Run? The Story Isn't Over Yet - RTTNews
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics to Present Topline Phase 1/2 OPGx-BEST1 Gene Therapy Data on September 9 - Quiver Quantitative
Opus Genetics Plans OPGx-BEST1 Data Webcast Sept. 9 | IRD Stock News - Stock Titan
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data - Yahoo Finance
Why is Opus Genetics stock rallying today? By Investing.com - Investing.com Nigeria
Why is Opus Genetics stock rallying today? - Investing.com
IRD | Opus Genetics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Citizens reiterates Opus Genetics stock rating on Viatris partnership potential By Investing.com - Investing.com Nigeria
Opus (IRD) Quarterly Figures: Profit Per Share Clears Its Benchmark in the Latest Session; Price Reaction - vinanet.vn
Opus (IRD) Earnings Report: Profit Per Share Clears Its Benchmark on the Day; After Results: The Market Price Declines 1.70% in the Current UpdateWeak Earnings Momentum - vinanet.vn
Opus Genetics, Inc. (NASDAQ: IRD) Share Price, IRD Stock News, IRD Share Price & Updates - Kalkine
Balyasny Asset Management L.P. Expands Opus Genetics Inc (IRD) S - GuruFocus
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics stock maintains buy rating ahead of trial data By Investing.com - Investing.com Canada
Citizens reiterates Opus Genetics stock rating ahead of trial data - Investing.com
Citizens reiterates Opus Genetics stock rating ahead of trial data By Investing.com - Investing.com India
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to "Hold" - MarketBeat
IRD Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.14 Beats Estimates, Though Shares Slip 2.96%Profitability Analysis - vinanet.vn
Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research - MarketBeat
Opus Genetics Q3 EPS Lifted by Brookline Capital Markets - MarketBeat
Brokers Set Expectations for Opus Genetics FY2030 Earnings - MarketBeat
Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy - Clinical Leader
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy - Glance by Eyes On Eyecare
Opus Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Opus Genetics Inc (IRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Opus Genetics (IRD) Gets a Buy from RBC Capital - The Globe and Mail
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Ear - GuruFocus
Opus Genetics (IRD) Q1 2026 Earnings: Deep EPS Miss Heightens Scrutiny on Clinical-Stage SpendingEarnings Trend Analysis - dars.gov.et
OPUS GENETICSMAY OFFER AND SELL UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
IRD Maintained by RBC Capital -- Price Target Lowered to $9.00 - GuruFocus
A. G. P. Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $9 to $10 - Moomoo
Opus GeneticsMay Offer And Sell Up To $300 Million Of SecuritiesSEC Filing - TradingView
Finanzdaten der Opus Genetics Inc-Aktie (IRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Opus Genetics Inc-Aktie (IRD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gagnon Robert E. | Chief Financial Officer |
Sep 03 '26 |
Sale |
4.54 |
28,000 |
127,212 |
556,375 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):